These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 11215571)

  • 1. [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients.
    Haapaniemi TH; Ahonen A; Torniainen P; Sotaniemi KA; Myllylä VV
    Mov Disord; 2001 Jan; 16(1):124-30. PubMed ID: 11215571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity.
    Kim SE; Lee WY; Choe YS; Kim JH
    Neurol Res; 1999 Apr; 21(3):255-61. PubMed ID: 10319333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.
    Berding G; Brücke T; Odin P; Brooks DJ; Kolbe H; Gielow P; Harke H; Knoop BO; Dengler R; Knapp WH
    Nuklearmedizin; 2003 Feb; 42(1):31-8. PubMed ID: 12601452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.
    Kim SE; Choi JY; Choe YS; Choi Y; Lee WY
    J Nucl Med; 2003 Jun; 44(6):870-6. PubMed ID: 12791812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.
    Seibyl JP; Marek KL; Quinlan D; Sheff K; Zoghbi S; Zea-Ponce Y; Baldwin RM; Fussell B; Smith EO; Charney DS; van Dyck C
    Ann Neurol; 1995 Oct; 38(4):589-98. PubMed ID: 7574455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography.
    Tatsch K; Schwarz J; Mozley PD; Linke R; Pogarell O; Oertel WH; Fieber RS; Hahn K; Kung HF
    Eur J Nucl Med; 1997 Apr; 24(4):415-21. PubMed ID: 9096093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dopamine transporter SPECT in patients with Parkinson's disease].
    Hamano T; Tsuchida T; Hirayama M; Fujiyama J; Mutoh T; Yonekura Y; Kuriyama M
    Kaku Igaku; 2000 Mar; 37(2):125-9. PubMed ID: 10783572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An
    Joling M; Vriend C; Raijmakers PGHM; van der Zande JJ; Lemstra AW; Berendse HW; Booij J; van den Heuvel OA
    Neuroimage Clin; 2019; 22():101755. PubMed ID: 30884365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.
    Benamer HT; Patterson J; Wyper DJ; Hadley DM; Macphee GJ; Grosset DG
    Mov Disord; 2000 Jul; 15(4):692-8. PubMed ID: 10928580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
    Ahlskog JE; Uitti RJ; O'Connor MK; Maraganore DM; Matsumoto JY; Stark KF; Turk MF; Burnett OL
    Mov Disord; 1999 Nov; 14(6):940-6. PubMed ID: 10584667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms.
    Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
    Nucl Med Commun; 2005 May; 26(5):421-6. PubMed ID: 15838424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrastriatal
    Nicastro N; Garibotto V; Burkhard PR
    BMC Neurol; 2020 May; 20(1):192. PubMed ID: 32416724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Extrastriatal
    Joling M; Vriend C; van den Heuvel OA; Raijmakers PGHM; Jones PA; Berendse HW; Booij J
    J Nucl Med; 2017 Jul; 58(7):1117-1123. PubMed ID: 27856628
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT.
    Varrone A; Sansone V; Pellecchia MT; Amboni M; Salvatore E; De Michele G; Filla A; Barone P; Pappatà S; Salvatore M
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1343-9. PubMed ID: 18283454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.